目的:分析硫酸镁在前置胎盘药物治疗中的临床疗效及应用价值。方法:收治前置胎盘孕妇48例,分为分析组和对比组各24例。分析组给予硫酸镁抑制宫缩、地塞米松促进胎肺成熟治疗,对比组给予绝对卧床休息、地塞米松促进胎肺成熟治疗,比较两...目的:分析硫酸镁在前置胎盘药物治疗中的临床疗效及应用价值。方法:收治前置胎盘孕妇48例,分为分析组和对比组各24例。分析组给予硫酸镁抑制宫缩、地塞米松促进胎肺成熟治疗,对比组给予绝对卧床休息、地塞米松促进胎肺成熟治疗,比较两组的临床治疗效果,如延长孕周数、新生儿体重以及1 min Apgar评分。结果:分析组孕妇的产前平均出血量、阴道流血平均停止时间优于对比组,分析组的延长孕周数、新生儿体重以及1 min Apgar评分显著高于对比组(P<0.05)。结论:硫酸镁在前置胎盘药物治疗中具有显著疗效,能够有效提升临床治疗效果,减少产前出血量与住院时间,延长孕周,改善胎儿预后。展开更多
AIM: To explore the capability of a monoclonal antibody (mAb) against murine endoglin to inhibit tumor angiogenesis and suppression of hepatoma growth in murine models. METHODS: A monoclonal antibody against murine en...AIM: To explore the capability of a monoclonal antibody (mAb) against murine endoglin to inhibit tumor angiogenesis and suppression of hepatoma growth in murine models. METHODS: A monoclonal antibody against murine endoglin was purified by affinity chromatography and passively transfused through tail veins in two murine hepatoma models. Tumor volume and survival time were observed at three-day intervals for 48 d. Microvessels in tumor tissues were detected by immunohistochemistry against CD31, and angiogenesis in vivo was determined by alginate encapsulated assay. In addition, tumor cell apoptosis was detected by TUNEL assay. RESULTS: Passive immunotherapy with anti-endoglin mAb could effectively suppress tumor growth, and prolonged the survival time of hepatoma-bearing mice. Angiogenesis was apparently inhibited within the tumor tissues, and the vascularization of alginate beads was also reduced in the mice passively transfused with anti- endoglin mAb. In addition, increased apoptotic cells were observed within the tumor tissues from the mice passively transfused with anti-endoglin mAb. CONCLUSION: Passive immunotherapy with anti- endoglin mAb effectively inhibits tumor growth via inhibiting tumor angiogenesis and increasing tumor cell apoptosis, which may be highly correlated with the blockage of endoglin-related signal pathway induced bya nti-endoglin mAb.展开更多
Injectable bovine collagen has been used clinically for years. But both the necessity of repeated injections to maintain corrections and the question of adverse allergic reactions developing from the use of a xenogeni...Injectable bovine collagen has been used clinically for years. But both the necessity of repeated injections to maintain corrections and the question of adverse allergic reactions developing from the use of a xenogenic collagen have been an area of serious concern. To overoome these adverse effects, we have developed injectable collagen preparations from human placenta. Gamma irradiation was used for sterilization and crosslinkins of the collagen.We observed the mouse immune respose to gamma-irradiated human placenta soluble and insoluble collagen following multiple injections. After six injections of these materials, no total IgG level increase was found, nor was antibody specifically directed against human collagen found.Mouse antibody levels were also observed following Zyderm II and Zyplast repetitive injections and following repetitive implantations of coated vicryl and chromic gut. No humoral immune response was found in this heterologous type system.展开更多
Retained placenta is a known cause of post-partum haemorrhage and maternal mortality. A recent systemic review has confirmed that the incidence of retained placenta had increased all over the world, which is more comm...Retained placenta is a known cause of post-partum haemorrhage and maternal mortality. A recent systemic review has confirmed that the incidence of retained placenta had increased all over the world, which is more common in developed countries. Failure of retroplacental myometrium contraction is the main cause of retained placenta. Maternal age greater than 35 years, grandmultipara, preterm labor, history of previous retained placenta, and caesarean section were the risk factors for retained placenta. Manual removal of the placenta has been the treatment of choice. Attempts had been made by clinician and researchers to find a safe, effective and reliable method to avoid the need for surgical intervention. The efficacy and safety of prostaglandin, nitroglycerin or acupuncture in the management of retained placenta are yet to be further evaluated. Nonetheless, till date only intraumbilical vein oxytocin has been studied extensively but with varied success. More randomized clinical trials are needed to address this issue. However, if immediate manual placenta removal service is unavailable, a trial of intra-umbilical vein oxytocin 100 IU at a totalvolume of at least 40 m L while preparing for transfer to a tertiary center or theatre may result in spontaneous expulsion of the placenta.展开更多
文摘目的:分析硫酸镁在前置胎盘药物治疗中的临床疗效及应用价值。方法:收治前置胎盘孕妇48例,分为分析组和对比组各24例。分析组给予硫酸镁抑制宫缩、地塞米松促进胎肺成熟治疗,对比组给予绝对卧床休息、地塞米松促进胎肺成熟治疗,比较两组的临床治疗效果,如延长孕周数、新生儿体重以及1 min Apgar评分。结果:分析组孕妇的产前平均出血量、阴道流血平均停止时间优于对比组,分析组的延长孕周数、新生儿体重以及1 min Apgar评分显著高于对比组(P<0.05)。结论:硫酸镁在前置胎盘药物治疗中具有显著疗效,能够有效提升临床治疗效果,减少产前出血量与住院时间,延长孕周,改善胎儿预后。
基金the National Natural Science Foundation of China, No. 30360115 and 30560048the Program for New Century Excellent Talents in University of China, No. NCET-05-0757the Foundation Project for Natural Science by the Education Department of Hainan Province of China, No. Hjkj200422
文摘AIM: To explore the capability of a monoclonal antibody (mAb) against murine endoglin to inhibit tumor angiogenesis and suppression of hepatoma growth in murine models. METHODS: A monoclonal antibody against murine endoglin was purified by affinity chromatography and passively transfused through tail veins in two murine hepatoma models. Tumor volume and survival time were observed at three-day intervals for 48 d. Microvessels in tumor tissues were detected by immunohistochemistry against CD31, and angiogenesis in vivo was determined by alginate encapsulated assay. In addition, tumor cell apoptosis was detected by TUNEL assay. RESULTS: Passive immunotherapy with anti-endoglin mAb could effectively suppress tumor growth, and prolonged the survival time of hepatoma-bearing mice. Angiogenesis was apparently inhibited within the tumor tissues, and the vascularization of alginate beads was also reduced in the mice passively transfused with anti- endoglin mAb. In addition, increased apoptotic cells were observed within the tumor tissues from the mice passively transfused with anti-endoglin mAb. CONCLUSION: Passive immunotherapy with anti- endoglin mAb effectively inhibits tumor growth via inhibiting tumor angiogenesis and increasing tumor cell apoptosis, which may be highly correlated with the blockage of endoglin-related signal pathway induced bya nti-endoglin mAb.
文摘Injectable bovine collagen has been used clinically for years. But both the necessity of repeated injections to maintain corrections and the question of adverse allergic reactions developing from the use of a xenogenic collagen have been an area of serious concern. To overoome these adverse effects, we have developed injectable collagen preparations from human placenta. Gamma irradiation was used for sterilization and crosslinkins of the collagen.We observed the mouse immune respose to gamma-irradiated human placenta soluble and insoluble collagen following multiple injections. After six injections of these materials, no total IgG level increase was found, nor was antibody specifically directed against human collagen found.Mouse antibody levels were also observed following Zyderm II and Zyplast repetitive injections and following repetitive implantations of coated vicryl and chromic gut. No humoral immune response was found in this heterologous type system.
文摘Retained placenta is a known cause of post-partum haemorrhage and maternal mortality. A recent systemic review has confirmed that the incidence of retained placenta had increased all over the world, which is more common in developed countries. Failure of retroplacental myometrium contraction is the main cause of retained placenta. Maternal age greater than 35 years, grandmultipara, preterm labor, history of previous retained placenta, and caesarean section were the risk factors for retained placenta. Manual removal of the placenta has been the treatment of choice. Attempts had been made by clinician and researchers to find a safe, effective and reliable method to avoid the need for surgical intervention. The efficacy and safety of prostaglandin, nitroglycerin or acupuncture in the management of retained placenta are yet to be further evaluated. Nonetheless, till date only intraumbilical vein oxytocin has been studied extensively but with varied success. More randomized clinical trials are needed to address this issue. However, if immediate manual placenta removal service is unavailable, a trial of intra-umbilical vein oxytocin 100 IU at a totalvolume of at least 40 m L while preparing for transfer to a tertiary center or theatre may result in spontaneous expulsion of the placenta.
